TireogenТиреоген
A peptide mixture extracted from young animal thyroid glands, described in a Russian report on thyroid hormones.
What the studies found
Comparison in people · 2017
Tireogen and Endoluten as adjuncts in autoimmune thyroiditis
Study of multiple preparations
- TSH at month four
- Standard care 7.14 ± 0.86, Tireogen 4.09 ± 0.12, combination 3.94 ± 0.12 mIU/L. Shared baseline 8.84 ± 1.09.The table marks both adjunctive arms as significantly different from standard care.
- Anti-thyroglobulin antibodies
- 83.32 ± 3.28, 77.41 ± 1.18 and 18.91 ± 1.65 IU/L in the three groups, respectively.The table marks both adjunctive arms. The narrative describes no antibody effect with Tireogen alone.
- Anti-thyroid peroxidase antibodies
- 361.24 ± 12.4, 357.23 ± 11.41 and 29.16 ± 2.54 IU/L, respectively. The table gives no significance mark for this row.
At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.
Study notes · methods, sources and limitations
Participants or model 218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.
Design 89 patients received standard treatment, 42 added Tireogen and 87 added Tireogen plus Endoluten. The reported schedules were two Tireogen capsules daily and one Endoluten capsule every three days for four months. Capsule mass is unspecified. The levothyroxine unit in the reproduction is anomalous.
Important limitations
- Allocation, masking and separate baseline values are unspecified. There was no Endoluten-only arm. The table marks an anti-thyroglobulin difference for Tireogen alone, while the narrative says Tireogen alone did not affect antibodies. The anti-TPO row gives no significance mark. The reproduction prints an anomalous levothyroxine unit. The exact background dose is uncertain.
- The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The design leaves allocation unspecified and the table gives one shared baseline.
Innovation in Aging. 2017;1(Suppl 1):324. PMCID PMC6243877. · Published conference abstract with author report
Comparison in people · 2006
Tireogen: institute clinical report (commercially hosted translation)
The report describes symptom and thyroid-hormone changes during adjunctive care.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 25 treated patients and 19 controls with primary hypothyroidism; report dates November 2005–January 2006
Important limitations
- Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated. Concurrent thyroid treatment is inadequately specified. This cannot establish a substitute for thyroid-hormone replacement or confirm durable thyroid restoration. Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.
Institute-attributed report, 2006; commercially hosted brochure pp. 73–74 · Institute report — commercial reproduction
About Tireogen
Identity / background source ↗
Research background
Tireogen is a thyroid-associated peptide preparation. A Medical Center report followed thyroid markers in primary hypothyroidism. A separate 218-person comparison evaluated Tireogen with and without Endoluten in autoimmune thyroiditis.
- Compound class
- Archival preparation lead
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
25 treated patients and 19 controls with primary hypothyroidism; report dates November 2005–January 2006
Study methods
Small adjunctive comparison; signed original, allocation and reporting require verification
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
New indexed primary abstracts and/or report reproductions linked; review depth shown per source
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Comparison in people · 2017
Tireogen and Endoluten as adjuncts in autoimmune thyroiditis
At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.
Study notes and original source
Tireogen and Endoluten as adjuncts in autoimmune thyroiditis
Oral Tireogen, or Tireogen plus Endoluten, alongside standard treatment · Published conference abstract with author report
D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · Innovation in Aging. 2017;1(Suppl 1):324. PMCID PMC6243877.
At four months the author table reports TSH of 7.14 with standard care, 4.09 with adjunctive Tireogen, and 3.94 mIU/L with the combination. Antibody findings are reported with inconsistencies between table and narrative.
Results and tables
Reported findings and study design
89 patients received standard treatment, 42 added Tireogen and 87 added Tireogen plus Endoluten. The reported schedules were two Tireogen capsules daily and one Endoluten capsule every three days for four months. Capsule mass is unspecified. The levothyroxine unit in the reproduction is anomalous.
Population or model 218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| TSH at month four | Standard care 7.14 ± 0.86, Tireogen 4.09 ± 0.12, combination 3.94 ± 0.12 mIU/L. Shared baseline 8.84 ± 1.09. | The table marks both adjunctive arms as significantly different from standard care. |
| Anti-thyroglobulin antibodies | 83.32 ± 3.28, 77.41 ± 1.18 and 18.91 ± 1.65 IU/L in the three groups, respectively. | The table marks both adjunctive arms. The narrative describes no antibody effect with Tireogen alone. |
| Anti-thyroid peroxidase antibodies | 361.24 ± 12.4, 357.23 ± 11.41 and 29.16 ± 2.54 IU/L, respectively. The table gives no significance mark for this row. |
The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The design leaves allocation unspecified and the table gives one shared baseline.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 218 adults aged 39–51: 89 standard treatment, 42 standard treatment plus Tireogen, 87 standard treatment plus Tireogen and Endoluten.
- Source reviewed
- Published 2017 conference abstract and authors’ reproduced report, PDF pages 16–17. The 2015 and 2017 presentations describe the same study program.
Study limitations
- Allocation, masking and separate baseline values are unspecified. There was no Endoluten-only arm.
- The table marks an anti-thyroglobulin difference for Tireogen alone, while the narrative says Tireogen alone did not affect antibodies. The anti-TPO row gives no significance mark.
- The reproduction prints an anomalous levothyroxine unit. The exact background dose is uncertain.
Reviewed 2026-11-16.
Comparison in people · 2006
Tireogen: institute clinical report (commercially hosted translation)
The report describes symptom and thyroid-hormone changes during adjunctive care.
Study notes and original source
Tireogen: institute clinical report (commercially hosted translation)
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
Format: PDF · Reviewed: Report reproduction reviewed
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2006; commercially hosted brochure pp. 73–74
The report describes symptom and thyroid-hormone changes during adjunctive care.
- Population / setting
- 25 treated patients and 19 controls with primary hypothyroidism; report dates November 2005–January 2006
- Source reviewed
- Brochure PDF pp. 73–74: methods/results text checked; selected population/table pages visually inspected. This is a provenance check, not authentication of the institute original.
Study limitations
- Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
- Concurrent thyroid treatment is inadequately specified. This cannot establish a substitute for thyroid-hormone replacement or confirm durable thyroid restoration.
- Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.
Reviewed 2026-10-05.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗